

Efficacy of a targeted selective treatment in dairy herds affected by clinical dictyocaulosis.

T. Lurier, Thomas Hilaire, Philippe Camuset, G. Bourgoin, Marie-Anne Arcangioli

► To cite this version:

T. Lurier, Thomas Hilaire, Philippe Camuset, G. Bourgoin, Marie-Anne Arcangioli. Efficacy of a targeted selective treatment in dairy herds affected by clinical dictyocaulosis.. 31st WORLD BUIATRICS CONGRESS, National Association of Spanish Specialists in Bovine Medicine (ANEMBE); World Association for Buiatrics (WAB), Sep 2022, Madrid, Spain. hal-03838494

HAL Id: hal-03838494 https://hal.inrae.fr/hal-03838494

Submitted on 3 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



EFFICACY OF A TARGETED SELECTIVE TREATMENT IN DAIRY HERDS AFFECTED BY CLINICAL DICTYOCAULOSIS

Thibaut LURIER^{1,2}, Thomas HILAIRE¹, Claire HENON¹, Philippe CAMUSET³, Gilles BOURGOIN^{1,4}, Marie-Anne ARCANGIOLI¹

1-VetAgro Sup, 2-UMR EpiA, 3- Caux Seine veterinary practice 4-UMR 5558



SEPTEMBER 4TH TO 8TH

MADRID 2022

www.wbc-madrid2022.com



Bovine dictyocaulosis

- Dictyocaulosis is a worldwide parasitic disease reported in most temperate country
- Prevalence ≈ 80% of herds with enzootic cough in pasture during summer (France, *Lurier et al. 2018*)
- Economic importance

Clinical outbreaks cost = **159-167€/cows** (Holzhauer et al., 2011) (Holzhauer et


 \Rightarrow Decreased milk production (30/50% of cost), mortality (30/50% of cost), extra AI + veterinary expense (12-15%)

At EU level : € 139 million [€ 86–225 million] in

cattle (Charlier et al. 2020)



Country with reported cases of dictyocaulosis



Relative economic impact of dictyocaulosis among other parasitic disease according to the climate in Europe

WBC 2022



Diagnostic in adult cattle (Lurier et al. 2018)

• Routine method : Baermann / Mc Kenna sedimentation

Sp = 100%, **Se** = 7.4%

- Broncho-alveolar Lavage (BAL)
 - Presence of eggs or larvae :

Sp = 100%, Se = 24.7 %

• Eosinophils proportion > 4.77% in BALF cytology

Sp = 85.2% & Se = 85.2%

• Serology not available in France, Seuil = 0.389 ODR


Sp = 85.7% & Se=76.2%



D. Viviparus L3 in feces



D. Viviparus adult in BALF



BALF cytology with eosinophils



Treatment of dictyocaulosis

- Most anthelmintic are effective against *D.viviparus*
 - Very few treatment failure reported : eprinomectine (Rigaud et al. 2019), Albendazol (Coles et al. 2010), Abamectine and moxidectine (Molento et al. 2006)
- Routinely
 - Blanket treatment applied to all cows without confirmatory diagnostic
 - Potential unnecessary treatment
 - Potential selection of **anthelmintic resistance** in *D. viviparus* or in other gastrointestinal nematodes
- No targeted selective treatment protocols assessed for Dictyocaulosis control in cattle



study dosign 1/2

Pilot study design 1/2

Objectives


- Assess the efficacy of a targeted selected treatment of dairy cattle for :
 - Resolving clinical manifestation of dictyocaulosis in the herd
 - Limit the incidence of the disease in non-treated animal

Methods

- Inclusion of herds with a veterinary dictyocaulosis suspicion in two French regions
- Confirmatory diagnosis by bronchoalveolar lavage and Mc Kenna sedimentation
- Targeted selective treatment of 50% of the herd with eprinomectine injectable
- Longitudinal follow up until 3 month post treatment



Pilot study design 2/2







Rational for treatment

Eprecis ND CEVA (eprinomectine)

- Posology 0.2 mg/kg
- Injectable eprinomectine (suitable for selective treatment)
- 2 weeks protection against reinfestation by *D.viviparus*

Treated animals

- Clinically affected (cough)
- Primiparous (naive cows => most at risk to amplify the presence D.viviparus)
- Post portum cows (until 15 days after calving)



Results : Initial visit

- Only 6 herd enrolled
- Diagnostic positive in 4/6 (66%) herds
 - 1 herd excluded (non-compliance with treatment protocol)
- Animal level prevalence
 - Primiparous
 6/9 LBA
 2/9 Mc Kenna
 - Multiparous
- 1/9 LBA 1/9 Mc Kenna
- Only 1/3 pooled Mc Kenna positive

			Eosinophil	Mc	Pooled
	Herd	Cows	%	Kenna	Mc kenna
Primiparous	А	5824	27,75	0	0
		5834	20,75	0	
		5813	4.75	0	
	В	1782	15	\bigcirc	
		1808	7.5	0	
		1777	7.5	(1)	
	с	763	2,5	0	0
		4385	3,5	0	
		769	21.5	0	
	D	8969	0,1	0	0
		2708	0 0	0	
		4365	0.5	0	
	E	1301	0	0	0
		1465	0	0	
		4627	1.2	0	
Multiparous	А	7064	4,2	0	
		3493	1	0	
		3489	16	\bigcirc	
	В	1581	0	0	
		1565	0	0	
		1642	2	0	
	с	3864	2	0	
		8525	3	0	
		827	1.4	0	
	D	8670	0,2	0	
		9912	0	0	
	E	6277	0	0	
		6679	0	0	
		M3	1.2	0	



Results : Follow-up

Primiparous

- All 9/9 primiparous (treated) were negative to LBA and Mc Kenna at D30 and D90
- Multiparous
 - 2 excluded cows
 - 1 treated (cough) replaced by another cows at D30
 - 1 culled at D90
 - 2/8 primiparous (not treated) were positive to LBA or Mc Kenna at D30 and D90

WBC 2022 Eprinomectine 0.2mg/kg Mc Kenna × Nea % of eosinophil in the BALF cytology Pos rimiparou 10 20 -• 10. 0 -75 50 Days after treatment

Individual follow-up of the BALF cytology (the black line is the positivity cutoff of the eosinophils %)

⇒ Incidence rate : 4.4%/month in non treated multiparous 2%/month for all susceptible cows



Clinical follow up : Tachypnea & lung auscultation modification

- Abnormal clinical examination at D0
 - 3/9 primiparous
 - 1/8 multiparous
- During follow-up
 - Persistence of the abnormal clinical signs in 2/4 primiparous and 1/1 multiparous
 - No newly clinically affected cows
- According to the farmer
 - Resolution of the clinical signs in 2/3 herds
 - Persistence of cough in 1 herd without needs for supplementary treatments



Discussion

Interest of the targeted selected treatment

- No re-infestation in primiparous cows
- No new clinical manifestation after treatment
- Low incidence (4.4%/month) of *D.viviparus* infestation in non-treated cows
- Few herds corresponding to the inclusion criteria
 - Dry weather limiting the contamination of the pasture
 - \Rightarrow Could have limited the number of lungworm outbreaks
 - \Rightarrow Could also have favored the good response to the targeted selected treatment
- Only a proof of concept without control groups
 - Need to be reproduced with a larger number of herds
 - The targeted selected treatment strategy needs to be compared with a blanket treatment strategy in a randomized control trial



Conclusion and take-home message

- Importance of the initial diagnosis
 - 2/6 herds presenting enzootic cough at pasture during summer without dictyocaulosis
 - Confirmation of the higher sensitivity of the bronchoalveolar lavage compared to the Mc Kenna sedimentation in adult cows
- Potential interest of a targeted selected treatment in dairy cows by treating
 - Clinically affected animals
 - Primiparous and newly introduced animals
 - Early post-partum cows

Intitulé de la direction/service



Acknowledgment

- This study was funded by CEVA France who provides the Eprecis ND and some financial supports
- We also acknowledge
 - The farmers who accept to participate to this study
 - Nathalie Menudier, Damien Remmy (CEVA) for their implication in this project

Thank you for your attention





RÉPUBLIQUE FRANÇAISE

Liberté Égalité Fraternité



VetAgro Sup

